Oligomerix
Company

Last deal

$2.49M

Amount

Grant

Stage

10.08.2022

Date

3

all rounds

$17.62M

Total amount

date founded

Financing round

General

About Company
Oligomerix develops target identification and validation technologies for neurodegenerative diseases.

Industry

Sector :

Subsector :

founded date

01.01.2006

Number of employees

Company Type

For Profit

Last funding type

Grant

IPO status

Private

Description

Founded in 2006, Oligomerix is a biopharmaceutical company focused on developing disease-modifying therapeutics for neurodegenerative diseases such as Alzheimer's and rare tauopathies. The company's novel research allows for the rapid generation of stable amyloid oligomers as drug discovery targets. Oligomerix specializes in small molecule therapeutics designed to treat Alzheimer's disease with an upstream approach, targeting aberrant tau proteins. The company's goal is to develop easy-to-administer and cost-effective therapies that significantly add to newly emerging high-cost therapeutic options. Oligomerix is headquartered in White Plains, New York, and has lab facilities at the Albert Einstein College of Medicine.
Contacts

Contact Email

Phone number

Social url

Similar Companies
999
Asceneuron

Asceneuron

Asceneuron is a biotech company that develops effective therapeutics for orphan tauopathies and Alzheimer's disease.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Lausanne, Switzerland

total rounds

4

total raised

$129.18M
Lysosomal Therapeutics

Lysosomal Therapeutics

Lysosomal Therapeutics is a company dedicated to research and development in the field of neurodegeneration.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Cambridge, MA, USA

total rounds

2

total raised

$24.8M

count Of Investments

4
Acumen Pharmaceuticals

Acumen Pharmaceuticals

Acumen is developing a drug to treat Alzheimer's disease.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Carmel, IN, USA

total rounds

7

total raised

$265.1M
Tranquis Therapeutics

Tranquis Therapeutics

Tranquis Therapeutics develops medicines to treat neurodegenerative and aging-related diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Therapeutics

Location

San Mateo, CA, USA

total rounds

1

total raised

$30M

Financials

Funding Rounds
8
3

Number of Funding Rounds

$17.62M

Money Raised

Their latest funding was raised on 10.08.2022. Their latest investor National Institute on Aging. Their latest round Grant

Date 
Funding Round 
Investors 
Money Raised 
Lead 
02.06.2022
$2.7M
National Institute on Aging

National Institute on Aging

The company invests in startups in the education and biotechnology industries.

Sector

General Industrials

Subsector

Diversified Industrials

Location

Bethesda, MD, USA

count Of Investments

83
National Institutes of Health

National Institutes of Health

NIH conducts research to improve health and reduce illness and disability.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Health Care, Software, Government

Location

Bethesda, MD, USA

total rounds

1

total raised

$5M

count Of Investments

827

count Of Exists

31
Co-Investors
Investors
6
3

Number of lead investors

6

Number of investors

Investor 
Lead 
Round 
Partners 
National Institute on Aging

National Institute on Aging

The company invests in startups in the education and biotechnology industries.

Sector

General Industrials

Subsector

Diversified Industrials

Location

Bethesda, MD, USA

count Of Investments

83
National Institutes of Health

National Institutes of Health

NIH conducts research to improve health and reduce illness and disability.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Health Care, Software, Government

Location

Bethesda, MD, USA

total rounds

1

total raised

$5M

count Of Investments

827

count Of Exists

31

Wheatley MedTech Partners

Wheatley MedTech Partners is a New York-based venture capital fund.

Sector

Closed End Investments

Subsector

Closed End Investments

count Of Investments

2

People

Founders
2

Eliot J. Davidowitz

Davidowitz has 20+ years of experience in academic and industrial research and development. Prior to founding Oligomerix, he was a Senior Scientist and Laboratory Manager at Q-RNA, Inc. Dr. Davidowitz received his B.S. from Cornell University, Ph.D. from Case Western Reserve University and completed an NIH postdoctoral fellowship at Albert Einstein College of Medicine. His academic work was in molecular and cellular biology and his industrial experience has focused on assay development for drug discovery targeting tau protein for Alzheimer’s disease.

current job

Oligomerix
Oligomerix

organization founded

1

Eliot J. Davidowitz

James Moe
James Moe

James Moe

Moe has 20+ years industrial experience having held senior management positions in product development working on international teams in both early and late stage diagnostic, biotechnology and biopharmaceutical companies including Gene-Trak/Amoco Technology Ventures/Vysis, bioMerieux, and Mosaic Technologies. Prior to founding Oligomerix, he was Director of Product Development at Pyrosequencing, Senior Molecular Biologist at Spire Biomedical, and Director of Product Development at Q-RNA, Inc. Dr. Moe received his Ph.D. degree in Molecular Biology/Molecular Biophysics from Wesleyan University, did his postdoctoral studies at Vanderbilt University in the Center for Molecular Toxicology where he was jointly appointed in the Biochemistry Department in the Medical School, and the Chemistry Department in the College of Arts and Sciences, and has an MBA degree with a concentration in entrepreneurial studies from Boston University.

current job

Oligomerix
Oligomerix

organization founded

1

James Moe

Employee Profiles
6
James Moe

James Moe

Co-Founder & CEO , Director, Principal Investigator

Eliot J. Davidowitz

Co-Founder

Jack Pasini

CCO

Vic Micati

Chairman

Activity

Recent News
2